Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Dec;72(6):1474–1478. doi: 10.1038/bjc.1995.532

Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

M R Horsman 1, M Nordsmark 1, M Høyer 1, J Overgaard 1
PMCID: PMC2034065  PMID: 8519662

Abstract

Hydralazine can substantially decrease blood flow and increase hypoxia in transplanted tumours. Previous indirect studies have suggested that hydralazine does not induce such effects in spontaneous tumours. We have now directly investigated the ability of hydralazine to increase hypoxia in both transplanted and spontaneous murine tumours by measuring tumour oxygen partial pressure (pO2) distributions using an Eppendorf oxygen electrode. Spontaneous tumours arose at different sites in CDF1 mice, while transplanted tumours were produced by implanting a C3H mouse mammary carcinoma on the backs of the same mouse strain. Measurements of pO2 were made in anaesthetised mice immediately before and 45 min after an intravenous injection of 5 mg kg-1 hydralazine. In the transplanted tumours hydralazine significantly decreased tumour oxygenation, such that the percentage of pO2 values < or = 5 mmHg increased from 45% to 87%, and median pO2 decreased from 5 to 3 mmHg. Similar significant changes were induced by hydralazine in the spontaneous tumours, the percentage of pO2 values < or = 5 mmHg increasing from 60% to 94% while the median pO2 values decreased from 8 to 2 mmHg. These results clearly show that there is no difference in the response of transplanted and spontaneous mouse tumours to hydralazine.

Full text

PDF
1474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Bremner J. C., Stratford I. J., Wood P. J. Can 31P magnetic resonance spectroscopy measurements of changes in experimental tumour metabolism be related to modification of oxygenation status? BJR Suppl. 1992;24:137–141. [PubMed] [Google Scholar]
  2. Adams G. E., Stratford I. J., Godden J., Howells N. Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1137–1139. doi: 10.1016/0360-3016(89)90268-x. [DOI] [PubMed] [Google Scholar]
  3. Barlogie B., Hittelman W., Spitzer G., Trujilo J. M., Hart J. S., Smallwood L., Drewinko B. Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res. 1977 Dec;37(12):4400–4407. [PubMed] [Google Scholar]
  4. Bhujwalla Z. M., Tozer G. M., Field S. B., Maxwell R. J., Griffiths J. R. The energy metabolism of RIF-1 tumours following hydralazine. Radiother Oncol. 1990 Nov;19(3):281–291. doi: 10.1016/0167-8140(90)90155-p. [DOI] [PubMed] [Google Scholar]
  5. Bremner J. C., Counsell C. J., Adams G. E., Stratford I. J., Wood P. J., Dunn J. F., Radda G. K. In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification. Br J Cancer. 1991 Nov;64(5):862–866. doi: 10.1038/bjc.1991.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bremner J. C., Stratford I. J., Bowler J., Adams G. E. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990 May;61(5):717–721. doi: 10.1038/bjc.1990.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chaplin D. J., Acker B., Olive P. L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1131–1135. doi: 10.1016/0360-3016(89)90267-8. [DOI] [PubMed] [Google Scholar]
  8. Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
  9. Field S. B., Burney I. A., Needham S., Maxwell R. J., Coggle J., Griffiths J. R. Are transplanted tumours suitable as models for studies on vasculature? Int J Radiat Biol. 1991 Jul-Aug;60(1-2):255–260. doi: 10.1080/09553009114551971. [DOI] [PubMed] [Google Scholar]
  10. Fisker R. V., Horsman M. R., Overgaard J. Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues. Acta Oncol. 1991;30(5):641–647. doi: 10.3109/02841869109092433. [DOI] [PubMed] [Google Scholar]
  11. Honess D. J., Bleehen N. M. Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice. Int J Radiat Oncol Biol Phys. 1992;22(5):953–961. doi: 10.1016/0360-3016(92)90794-i. [DOI] [PubMed] [Google Scholar]
  12. Horsman M. R., Christensen K. L., Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia. 1989 Mar-Apr;5(2):123–136. doi: 10.3109/02656738909140442. [DOI] [PubMed] [Google Scholar]
  13. Horsman M. R., Christensen K. L., Overgaard J. Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure. Int J Radiat Oncol Biol Phys. 1992;22(3):455–458. doi: 10.1016/0360-3016(92)90852-9. [DOI] [PubMed] [Google Scholar]
  14. Höckel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., Knapstein P. G., Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993 Jan;26(1):45–50. doi: 10.1016/0167-8140(93)90025-4. [DOI] [PubMed] [Google Scholar]
  15. Kallinowski F., Zander R., Hoeckel M., Vaupel P. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):953–961. doi: 10.1016/0360-3016(90)90018-f. [DOI] [PubMed] [Google Scholar]
  16. Kalmus J., Okunieff P., Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors. Cancer Res. 1990 Jan 1;50(1):15–19. [PubMed] [Google Scholar]
  17. Lemmon M. J., Brown J. M. Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1435–1440. doi: 10.1016/0360-3016(91)90317-w. [DOI] [PubMed] [Google Scholar]
  18. Lin J. C., Song C. W. Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice. Radiat Res. 1990 Nov;124(2):171–177. [PubMed] [Google Scholar]
  19. Nordsmark M., Grau C., Horsman M. R., Jörgensen H. S., Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol. 1995;34(3):329–334. doi: 10.3109/02841869509093984. [DOI] [PubMed] [Google Scholar]
  20. Okunieff P., Kallinowski F., Vaupel P., Neuringer L. J. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy. J Natl Cancer Inst. 1988 Jul 20;80(10):745–750. doi: 10.1093/jnci/80.10.745. [DOI] [PubMed] [Google Scholar]
  21. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980 Nov;6(11):1507–1517. doi: 10.1016/0360-3016(80)90008-5. [DOI] [PubMed] [Google Scholar]
  22. Rofstad E. K., DeMuth P., Fenton B. M., Sutherland R. M. 31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Cancer Res. 1988 Oct 1;48(19):5440–5446. [PubMed] [Google Scholar]
  23. Rowell N. P., Clark K. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status. Radiother Oncol. 1990 Aug;18(4):293–298. doi: 10.1016/0167-8140(90)90109-a. [DOI] [PubMed] [Google Scholar]
  24. Rowell N. P., Flower M. A., McCready V. R., Cronin B., Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol. 1990 Aug;18(4):283–292. doi: 10.1016/0167-8140(90)90108-9. [DOI] [PubMed] [Google Scholar]
  25. Skarsgard L. D., Chaplin D. J., Wilson D. J., Skwarchuk M. W., Vinczan A., Kristl J. The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int J Radiat Oncol Biol Phys. 1992;22(4):737–741. doi: 10.1016/0360-3016(92)90514-i. [DOI] [PubMed] [Google Scholar]
  26. Tozer G. M., Maxwell R. J., Griffiths J. R., Pham P. Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension. Br J Cancer. 1990 Oct;62(4):553–560. doi: 10.1038/bjc.1990.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Voorhees W. D., 3rd, Babbs C. F. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol. 1982 Oct;18(10):1027–1033. doi: 10.1016/0277-5379(82)90252-8. [DOI] [PubMed] [Google Scholar]
  28. Wood P. J., Stratford I. J., Sansom J. M., Cattanach B. M., Quinney R. M., Adams G. E. The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys. 1992;22(3):473–476. doi: 10.1016/0360-3016(92)90856-d. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES